Kidney cancer drug study halted after just 6 patients
NCT ID NCT03846128
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if the amount of sunitinib in the blood affects side effects and how well the drug works in people with metastatic kidney cancer. Researchers planned to collect extra blood samples during routine visits from patients starting sunitinib as their first treatment. However, the study was terminated early after enrolling only 6 participants, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib
What this could lead to
If successful, this could help doctors personalize sunitinib dosing to reduce severe side effects while maintaining effectiveness.
What could go wrong
The study was terminated early with only 6 participants, so results are very limited and may not apply broadly. No new treatment was tested.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de ROUEN
Rouen, 76031, France